An Update On Data Obtained From DCVax-Direct Phase I Trial Presented By Northwest Biotherapeutics, Inc (NASDAQ: NWBO)


Northwest Biotherapeutics (NASDAQ:NWBO) is responsible for the development of DCVax. It was announced that a more detailed analysis on Phase I DCVax-Direct Trial data was presented by Dr. Marnix Bosch.

The purpose and importance of DC Vax-Direct Development

DC Vax-Direct is a personalized immune therapy designed to treat patients with solid tumors that doctors are unable to operate on.

The development of DC Vax-Direct is considered the next critical step in improving the quality and efficiency of treatment for patients that suffer from cancer. Through the use of this treatment, it has been predicted that toxic-abundant treatment therapies such as Chemotherapy will no longer be considered the only option.

The Results of the Phase I trial

The important thing to note with regards to the Phase I trial is the fact that all those that participated in the trial, had been let down through current medical regimes. Throughout the participants, there are patients that failed as many as five – six different types of treatments before this test trial.

During this Phase, a total of 40 patients were participating, a variety of different types of solid cancerous tumors were spread out via the patients that were participating. The administration of DC Vax-Direct was an injection directly into a singular tumor, this process is image guided.

Throughout the participants, majority of patients received a maximum of three treatments using DC Vax-Direct. It was found that the top 20% of these patients have survived for an additional two years, the longest of which currently is at 3-years expanded life expectancy.

The survival rate of those treated by DC Vax-Direct

The survival rate for cancers such as pancreatic, lung, ovarian, sarcoma and other similar ailments drastically increase for patients under DC Vax-Direct. The normal life span of patients with similar ailments is approximately 12.3 months. However, those who received DC Vax-Direct treatment had an average survival rate of up to 26.7 months.

The diversity of the various cancers that were treated through DC Vax-Direct is equivalent to 800,000 new cases of cancer each year, once these cancers progress to the inoperable metastatic stage, as of right now – there are no effectivetreatments.


Leave A Reply